<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01464827</url>
  </required_header>
  <id_info>
    <org_study_id>M11-652</org_study_id>
    <secondary_id>2010-022455-31</secondary_id>
    <nct_id>NCT01464827</nct_id>
  </id_info>
  <brief_title>ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients</brief_title>
  <official_title>A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 With Ritonavir (ABT-450/r) in Combination With ABT-267 and/or ABT-333 With and Without Ribavirin (RBV) for 8, 12 or 24 Weeks in Treatment-Naïve and Null Responder Subjects With Genotype 1 Chronic Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of combination direct-acting antiviral agents (DAA) with or without ribavirin
      (RBV) in patients with chronic Hepatitis C Virus (HCV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A study to evaluate the safety and effectiveness of experimental drugs ABT-450, ABT-267 (also
      known as ombitasvir), ABT-333 (also known as dasabuvir), ritonavir, and ribavirin in
      participants with HCV. The study will test the safety and effects of combinations of these
      drugs in treatments up to 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>From the time of study drug administration until 30 days following discontinuation of study drug administration (up to 28 weeks).</time_frame>
    <description>An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment.
The investigator assessed the relationship of each AE to the use of direct-acting antiviral agents (DAAs) and to ribavirin, and rated the severity of each event as either:
Mild: The AE was transient and easily tolerated by the participant; Moderate: The AE caused the participant discomfort and interrupted usual activities; Severe: The AE caused considerable interference with the participant's usual activities and could have been incapacitating or life-threatening.
A serious adverse event was any event that resulted in death, was life-threatening, resulted in or prolonged hospitalization, resulted in a congenital anomaly or persistent or significant disability or was any other important medical event requiring medical or surgical intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose for 8 Weeks Versus 12 Weeks of Treatment With 3 DAAs and Ribavirin</measure>
    <time_frame>Post Treatment Week 24</time_frame>
    <description>The percentage of participants achieving sustained virologic response 24 weeks after the last dose of study drug (SVR24), defined as hepatitis C virus (HCV) ribonucleic acid (RNA) less than the lower limit of quantitation (LLOQ), without any confirmed quantifiable (≥ LLOQ) post-treatment value before that time point. HCV RNA levels were measured from plasma by a central laboratory. The LLOQ for the assay was 25 IU/mL.
The primary efficacy endpoint was the comparison between treatment-naïve participants following 8 weeks of treatment with 3 DAAs and ribavirin and those with 12 weeks of treatment with 3 DAAs and ribavirin (Group A versus Group G).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment of Different Durations With 3 Direct-acting Antiviral Agents (DAAs) and Ribavirin</measure>
    <time_frame>Post-Treatment Week 24</time_frame>
    <description>This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks after the last dose of study drug (HCV RNA &lt; LLOQ at post-treatment Week 24) following treatment with 3 DAAs (ABT-450/ritonavir, ABT-267, and ABT-333) and ribavirin in both treatment naïve and null-responder participants for 8 weeks (Group A) versus 12 weeks (Groups F + G + K + L) versus 24 weeks (Groups H + I + M + N).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 2 DAAs and Ribavirin Versus 3 DAAs and Ribavirin</measure>
    <time_frame>Post-Treatment Week 24</time_frame>
    <description>This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks post-dose (HCV RNA &lt; LLOQ at post-treatment Week 24) following treatment with 2 DAAs (ABT-450/ritonavir plus ABT-333 [Group B] or ABT-450/ritonavir plus ABT-267 [Groups C + D + J]) and ribavirin versus 3 DAAs (ABT-450/ritonavir plus ABT-333 and ABT-267) and ribavirin (Groups F + G + K + L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 3 DAAs With Versus Without Ribavirin</measure>
    <time_frame>Post-Treatment Week 24</time_frame>
    <description>This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks post-dose (HCV RNA &lt; LLOQ at post-treatment Week 24) following treatment with 3 DAAs with or without ribavirin (Group E versus Groups F + G + K + L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose in Treatment-naïve Versus Null-responders</measure>
    <time_frame>Post-Treatment Week 24</time_frame>
    <description>This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks post-dose (HCV RNA &lt; LLOQ at post-treatment Week 24) following treatment with 3 DAAs and ribavirin in participants who were treatment-naïve versus those who were null-responders to previous HCV therapy (Groups F + G + H + I versus Groups K + L + M + N).</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">580</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Hepatitis C (HCV)</condition>
  <condition>Hepatitis C Genotype 1</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naïve participants received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group J</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-450</intervention_name>
    <description>ABT-450 tablets</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group J</arm_group_label>
    <arm_group_label>Group K</arm_group_label>
    <arm_group_label>Group L</arm_group_label>
    <arm_group_label>Group M</arm_group_label>
    <arm_group_label>Group N</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-333</intervention_name>
    <description>ABT-333 tablets</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group K</arm_group_label>
    <arm_group_label>Group L</arm_group_label>
    <arm_group_label>Group M</arm_group_label>
    <arm_group_label>Group N</arm_group_label>
    <other_name>Dasabuvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-267</intervention_name>
    <description>ABT-267 tablets</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group J</arm_group_label>
    <arm_group_label>Group K</arm_group_label>
    <arm_group_label>Group L</arm_group_label>
    <arm_group_label>Group M</arm_group_label>
    <arm_group_label>Group N</arm_group_label>
    <other_name>Ombitasvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group J</arm_group_label>
    <arm_group_label>Group K</arm_group_label>
    <arm_group_label>Group L</arm_group_label>
    <arm_group_label>Group M</arm_group_label>
    <arm_group_label>Group N</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir capsules</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group J</arm_group_label>
    <arm_group_label>Group K</arm_group_label>
    <arm_group_label>Group L</arm_group_label>
    <arm_group_label>Group M</arm_group_label>
    <arm_group_label>Group N</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 18-70 years old, inclusive

          -  Females must be post-menopausal for more than 2 years or surgically sterile or
             practicing specific forms of birth control

          -  Chronic hepatitis C virus (HCV), genotype 1 infection

          -  Treatment-naive OR null-responders to previous treatment with pegylated interferon
             (pegIFN) and ribavirin (at least 12 weeks of treatment and failure to achieve a 2
             log10 HCV RNA decrease at Week 12)

          -  No evidence of liver cirrhosis

        Exclusion Criteria:

          -  Significant liver disease with any cause other than HCV as the primary cause

          -  Positive hepatitis B surface antigen and anti-human immunodeficiency virus antibody

          -  Positive screen for drugs and alcohol

          -  Significant sensitivity to any drug

          -  Use of contraindicated or prohibited medications within 1 month of dosing

          -  Abnormal laboratory tests
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Cohen, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57583</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55530</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55385</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55500</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55382</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 61042</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43651</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43652</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 59130</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43565</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43910</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43572</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43584</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43917</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55384</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44610</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55531</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55536</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55540</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55527</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44621</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43576</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55383</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 59124</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43568</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55901</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43588</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55534</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43656</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43655</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0848</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43913</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43587</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43661</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43569</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44608</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55526</name>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43566</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 59133</name>
      <address>
        <city>Monticello</city>
        <state>New York</state>
        <zip>12701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43586</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43573</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55532</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55386</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55538</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55522</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55542</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55533</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43665</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43585</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55539</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 56622</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43592</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55723</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43659</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 59132</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43577</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43662</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43666</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43574</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43578</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-5124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55387</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44850</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44849</name>
      <address>
        <city>Herston</city>
        <zip>QLD 4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44852</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44084</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43905</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 1H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44755</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44758</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 58884</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 58887</name>
      <address>
        <city>Marseilles</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 58886</name>
      <address>
        <city>Montpellier - Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44754</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 58889</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44760</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 59304</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 59303</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 46103</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 46106</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 46102</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 58922</name>
      <address>
        <city>Kiel</city>
        <zip>24146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 46105</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44847</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43672</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43675</name>
      <address>
        <city>San Juan</city>
        <zip>00936-5067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 46485</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45363</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45668</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 46484</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45667</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45671</name>
      <address>
        <city>Majadahonda (Madrid)</city>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 46583</name>
      <address>
        <city>Seville</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45405</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57545</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 59262</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57547</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 58811</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57882</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57543</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2011</study_first_submitted>
  <study_first_submitted_qc>November 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2011</study_first_posted>
  <results_first_submitted>December 23, 2014</results_first_submitted>
  <results_first_submitted_qc>December 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2015</results_first_posted>
  <disposition_first_submitted>March 25, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 25, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 21, 2014</disposition_first_posted>
  <last_update_submitted>April 2, 2015</last_update_submitted>
  <last_update_submitted_qc>April 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Genotype 1</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Interferon-Free</keyword>
  <keyword>HCV</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a Phase 2, open-label, randomized, combination treatment study of multiple doses of ABT-450/ritonavir, and ABT-267 and/or ABT-333 with or without ribavirin in hepatitis C virus (HCV) genotype 1-infected treatment-naïve patients and previous null responders to pegylated interferon (pegIFN) and ribavirin treatment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Group C</title>
          <description>Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Group D</title>
          <description>Treatment-naïve participants received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Group E</title>
          <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Group F</title>
          <description>Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Group G</title>
          <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
        </group>
        <group group_id="P8">
          <title>Group H</title>
          <description>Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
        </group>
        <group group_id="P9">
          <title>Group I</title>
          <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
        </group>
        <group group_id="P10">
          <title>Group J</title>
          <description>Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
        </group>
        <group group_id="P11">
          <title>Group K</title>
          <description>Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
        </group>
        <group group_id="P12">
          <title>Group L</title>
          <description>Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
        </group>
        <group group_id="P13">
          <title>Group M</title>
          <description>Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
        </group>
        <group group_id="P14">
          <title>Group N</title>
          <description>Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="80"/>
                <participants group_id="P6" count="39"/>
                <participants group_id="P7" count="41"/>
                <participants group_id="P8" count="40"/>
                <participants group_id="P9" count="40"/>
                <participants group_id="P10" count="47"/>
                <participants group_id="P11" count="23"/>
                <participants group_id="P12" count="23"/>
                <participants group_id="P13" count="23"/>
                <participants group_id="P14" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="79"/>
                <participants group_id="P6" count="39"/>
                <participants group_id="P7" count="40"/>
                <participants group_id="P8" count="40"/>
                <participants group_id="P9" count="40"/>
                <participants group_id="P10" count="45"/>
                <participants group_id="P11" count="23"/>
                <participants group_id="P12" count="22"/>
                <participants group_id="P13" count="23"/>
                <participants group_id="P14" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="72"/>
                <participants group_id="P6" count="38"/>
                <participants group_id="P7" count="37"/>
                <participants group_id="P8" count="37"/>
                <participants group_id="P9" count="37"/>
                <participants group_id="P10" count="44"/>
                <participants group_id="P11" count="21"/>
                <participants group_id="P12" count="21"/>
                <participants group_id="P13" count="21"/>
                <participants group_id="P14" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population (participants who received at least 1 dose of direct-acting antiviral agent)</population>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Group C</title>
          <description>Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Group D</title>
          <description>Treatment-naïve participants received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Group E</title>
          <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Group F</title>
          <description>Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Group G</title>
          <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Group H</title>
          <description>Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
        </group>
        <group group_id="B9">
          <title>Group I</title>
          <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
        </group>
        <group group_id="B10">
          <title>Group J</title>
          <description>Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
        </group>
        <group group_id="B11">
          <title>Group K</title>
          <description>Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
        </group>
        <group group_id="B12">
          <title>Group L</title>
          <description>Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
        </group>
        <group group_id="B13">
          <title>Group M</title>
          <description>Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
        </group>
        <group group_id="B14">
          <title>Group N</title>
          <description>Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
        </group>
        <group group_id="B15">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="39"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="79"/>
            <count group_id="B6" value="39"/>
            <count group_id="B7" value="40"/>
            <count group_id="B8" value="40"/>
            <count group_id="B9" value="40"/>
            <count group_id="B10" value="45"/>
            <count group_id="B11" value="23"/>
            <count group_id="B12" value="22"/>
            <count group_id="B13" value="23"/>
            <count group_id="B14" value="20"/>
            <count group_id="B15" value="571"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.1" spread="9.99"/>
                    <measurement group_id="B2" value="50.8" spread="9.84"/>
                    <measurement group_id="B3" value="51.1" spread="8.07"/>
                    <measurement group_id="B4" value="49.0" spread="10.59"/>
                    <measurement group_id="B5" value="48.3" spread="10.53"/>
                    <measurement group_id="B6" value="49.4" spread="9.72"/>
                    <measurement group_id="B7" value="51.0" spread="11.08"/>
                    <measurement group_id="B8" value="51.5" spread="11.95"/>
                    <measurement group_id="B9" value="51.5" spread="9.78"/>
                    <measurement group_id="B10" value="50.6" spread="11.19"/>
                    <measurement group_id="B11" value="48.5" spread="12.91"/>
                    <measurement group_id="B12" value="51.2" spread="12.07"/>
                    <measurement group_id="B13" value="51.5" spread="9.06"/>
                    <measurement group_id="B14" value="54.6" spread="11.78"/>
                    <measurement group_id="B15" value="50.3" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="22"/>
                    <measurement group_id="B9" value="24"/>
                    <measurement group_id="B10" value="18"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="10"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="8"/>
                    <measurement group_id="B15" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="18"/>
                    <measurement group_id="B9" value="16"/>
                    <measurement group_id="B10" value="27"/>
                    <measurement group_id="B11" value="16"/>
                    <measurement group_id="B12" value="12"/>
                    <measurement group_id="B13" value="15"/>
                    <measurement group_id="B14" value="12"/>
                    <measurement group_id="B15" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment.
The investigator assessed the relationship of each AE to the use of direct-acting antiviral agents (DAAs) and to ribavirin, and rated the severity of each event as either:
Mild: The AE was transient and easily tolerated by the participant; Moderate: The AE caused the participant discomfort and interrupted usual activities; Severe: The AE caused considerable interference with the participant's usual activities and could have been incapacitating or life-threatening.
A serious adverse event was any event that resulted in death, was life-threatening, resulted in or prolonged hospitalization, resulted in a congenital anomaly or persistent or significant disability or was any other important medical event requiring medical or surgical intervention.</description>
        <time_frame>From the time of study drug administration until 30 days following discontinuation of study drug administration (up to 28 weeks).</time_frame>
        <population>Safety population. Treatment groups differing only in ABT-450 dose (100 mg, 150 mg or 200 mg) were combined for safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Group C + D</title>
            <description>Treatment-naïve participants received ABT-450 (100 mg or 200 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Group E</title>
            <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Group F + G</title>
            <description>Treatment-naïve participants received ABT-450 (100 mg or 150 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Group H + I</title>
            <description>Treatment-naïve participants received ABT-450 (100 mg or 150 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Group J</title>
            <description>Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Group K + L</title>
            <description>Participants who were null-responders to previous HCV treatment received ABT-450 (100 mg or 150 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Group M + N</title>
            <description>Participants who were null-responders to previous HCV treatment received ABT-450 (100 mg or 150 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment.
The investigator assessed the relationship of each AE to the use of direct-acting antiviral agents (DAAs) and to ribavirin, and rated the severity of each event as either:
Mild: The AE was transient and easily tolerated by the participant; Moderate: The AE caused the participant discomfort and interrupted usual activities; Severe: The AE caused considerable interference with the participant's usual activities and could have been incapacitating or life-threatening.
A serious adverse event was any event that resulted in death, was life-threatening, resulted in or prolonged hospitalization, resulted in a congenital anomaly or persistent or significant disability or was any other important medical event requiring medical or surgical intervention.</description>
          <population>Safety population. Treatment groups differing only in ABT-450 dose (100 mg, 150 mg or 200 mg) were combined for safety analyses.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="79"/>
                <count group_id="O6" value="80"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="45"/>
                <count group_id="O9" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="68"/>
                    <measurement group_id="O5" value="71"/>
                    <measurement group_id="O6" value="77"/>
                    <measurement group_id="O7" value="42"/>
                    <measurement group_id="O8" value="39"/>
                    <measurement group_id="O9" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any adverse event at least possibly DAA-related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="57"/>
                    <measurement group_id="O6" value="68"/>
                    <measurement group_id="O7" value="35"/>
                    <measurement group_id="O8" value="30"/>
                    <measurement group_id="O9" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any severe adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE leading to discontinuation of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE leading to interruption of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE leading to ribavirin dose modification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fatal adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose for 8 Weeks Versus 12 Weeks of Treatment With 3 DAAs and Ribavirin</title>
        <description>The percentage of participants achieving sustained virologic response 24 weeks after the last dose of study drug (SVR24), defined as hepatitis C virus (HCV) ribonucleic acid (RNA) less than the lower limit of quantitation (LLOQ), without any confirmed quantifiable (≥ LLOQ) post-treatment value before that time point. HCV RNA levels were measured from plasma by a central laboratory. The LLOQ for the assay was 25 IU/mL.
The primary efficacy endpoint was the comparison between treatment-naïve participants following 8 weeks of treatment with 3 DAAs and ribavirin and those with 12 weeks of treatment with 3 DAAs and ribavirin (Group A versus Group G).</description>
        <time_frame>Post Treatment Week 24</time_frame>
        <population>Intent-to-treat population (all participants who received at least 1 dose of direct-acting antiviral agent); participants with missing data were counted as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Group D</title>
            <description>Treatment-naïve participants received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Group E</title>
            <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Group F</title>
            <description>Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Group G</title>
            <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Group H</title>
            <description>Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
          </group>
          <group group_id="O9">
            <title>Group I</title>
            <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
          </group>
          <group group_id="O10">
            <title>Group J</title>
            <description>Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
          </group>
          <group group_id="O11">
            <title>Group K</title>
            <description>Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
          </group>
          <group group_id="O12">
            <title>Group L</title>
            <description>Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
          </group>
          <group group_id="O13">
            <title>Group M</title>
            <description>Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
          </group>
          <group group_id="O14">
            <title>Group N</title>
            <description>Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose for 8 Weeks Versus 12 Weeks of Treatment With 3 DAAs and Ribavirin</title>
          <description>The percentage of participants achieving sustained virologic response 24 weeks after the last dose of study drug (SVR24), defined as hepatitis C virus (HCV) ribonucleic acid (RNA) less than the lower limit of quantitation (LLOQ), without any confirmed quantifiable (≥ LLOQ) post-treatment value before that time point. HCV RNA levels were measured from plasma by a central laboratory. The LLOQ for the assay was 25 IU/mL.
The primary efficacy endpoint was the comparison between treatment-naïve participants following 8 weeks of treatment with 3 DAAs and ribavirin and those with 12 weeks of treatment with 3 DAAs and ribavirin (Group A versus Group G).</description>
          <population>Intent-to-treat population (all participants who received at least 1 dose of direct-acting antiviral agent); participants with missing data were counted as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="79"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="40"/>
                <count group_id="O8" value="40"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="45"/>
                <count group_id="O11" value="23"/>
                <count group_id="O12" value="22"/>
                <count group_id="O13" value="23"/>
                <count group_id="O14" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5"/>
                    <measurement group_id="O2" value="82.9"/>
                    <measurement group_id="O3" value="84.6"/>
                    <measurement group_id="O4" value="92.5"/>
                    <measurement group_id="O5" value="88.6"/>
                    <measurement group_id="O6" value="97.4"/>
                    <measurement group_id="O7" value="95.0"/>
                    <measurement group_id="O8" value="92.5"/>
                    <measurement group_id="O9" value="90.0"/>
                    <measurement group_id="O10" value="88.9"/>
                    <measurement group_id="O11" value="91.3"/>
                    <measurement group_id="O12" value="95.5"/>
                    <measurement group_id="O13" value="91.3"/>
                    <measurement group_id="O14" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy endpoint was the comparison of the percentage of treatment-naïve participants with SVR24 after treatment with 3 DAAs (at the 150 mg ABT-450 dose) and ribavirin for 8 weeks (Group A) versus 12 weeks (Group G).
Logistic regression with baseline log10 HCV RNA level, treatment group, Interleukin 28B genotype (CC or non-CC), HCV subgenotype (1a or non-1a), and geographic region (US or non-US) as predictors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.406</p_value>
            <p_value_desc>No adjustment for multiple comparison. Pre-specified 2-sided significance level of 0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>2.61</ci_upper_limit>
            <estimate_desc>Odds ratio: Group A : Group G</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment of Different Durations With 3 Direct-acting Antiviral Agents (DAAs) and Ribavirin</title>
        <description>This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks after the last dose of study drug (HCV RNA &lt; LLOQ at post-treatment Week 24) following treatment with 3 DAAs (ABT-450/ritonavir, ABT-267, and ABT-333) and ribavirin in both treatment naïve and null-responder participants for 8 weeks (Group A) versus 12 weeks (Groups F + G + K + L) versus 24 weeks (Groups H + I + M + N).</description>
        <time_frame>Post-Treatment Week 24</time_frame>
        <population>Intent-to-treat population; participants with missing data were counted as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Groups F + G + K + L</title>
            <description>Participants (treatment-naïve and null-responders) received ABT-450 (100 mg or 150 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Groups H + I + M + N</title>
            <description>Participants (treatment-naïve and null-responders) received ABT-450 (100 mg or 150 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment of Different Durations With 3 Direct-acting Antiviral Agents (DAAs) and Ribavirin</title>
          <description>This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks after the last dose of study drug (HCV RNA &lt; LLOQ at post-treatment Week 24) following treatment with 3 DAAs (ABT-450/ritonavir, ABT-267, and ABT-333) and ribavirin in both treatment naïve and null-responder participants for 8 weeks (Group A) versus 12 weeks (Groups F + G + K + L) versus 24 weeks (Groups H + I + M + N).</description>
          <population>Intent-to-treat population; participants with missing data were counted as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5"/>
                    <measurement group_id="O2" value="95.2"/>
                    <measurement group_id="O3" value="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The percentage of participants with SVR24 after treatment for 8 weeks versus 12 weeks was compared using logistic regression with treatment group, baseline log10 HCV RNA level, HCV subgenotype (1a or non-1a), geographic region (US or non-US), Interleukin 28B genotype (CC or non-CC), and ABT-450/ritonavir dose and population (treatment-naïve or null-responders) as predictors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.266</p_value>
            <p_value_desc>No adjustment for multiple comparison. Pre-specified 2-sided significance level of 0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>2.02</ci_upper_limit>
            <estimate_desc>Odds ratio: Group A : Groups [F + G + K + L]</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The percentage of participants with SVR24 after treatment for 8 weeks versus 24 weeks was compared using logistic regression with treatment group, baseline log10 HCV RNA level, HCV subgenotype (1a or non-1a), geographic region (US or non-US), Interleukin 28B genotype (CC or non-CC), ABT-450/ritonavir dose and population (treatment-naïve or null-responders) as predictors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.525</p_value>
            <p_value_desc>No adjustment for multiple comparison. Pre-specified 2-sided significance level of 0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>2.40</ci_upper_limit>
            <estimate_desc>Odds ratio: Group A : Groups [H + I + M + N]</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The percentage of participants with SVR24 after treatment for 12 weeks versus 24 weeks was compared using logistic regression with treatment group, baseline log10 HCV RNA level, HCV subgenotype (1a or non-1a), geographic region (US or non-US), Interleukin 28B genotype (CC or non-CC), ABT-450/ritonavir dose and population (treatment-naïve or null-responders) as predictors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.375</p_value>
            <p_value_desc>No adjustment for multiple comparison. Pre-specified 2-sided significance level of 0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>4.92</ci_upper_limit>
            <estimate_desc>Odds ratio: Groups [F + G + K + L] : Groups [H + I + M + N]</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 2 DAAs and Ribavirin Versus 3 DAAs and Ribavirin</title>
        <description>This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks post-dose (HCV RNA &lt; LLOQ at post-treatment Week 24) following treatment with 2 DAAs (ABT-450/ritonavir plus ABT-333 [Group B] or ABT-450/ritonavir plus ABT-267 [Groups C + D + J]) and ribavirin versus 3 DAAs (ABT-450/ritonavir plus ABT-333 and ABT-267) and ribavirin (Groups F + G + K + L).</description>
        <time_frame>Post-Treatment Week 24</time_frame>
        <population>Intent-to-treat population; participants with missing data were counted as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Group B</title>
            <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Groups C + D + J</title>
            <description>Participants (treatment-naïve and null-responders) received ABT-450 (100 mg or 200 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Groups F + G + K + L</title>
            <description>Participants (treatment-naïve and null-responders) received ABT-450 (100 mg or 150 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 2 DAAs and Ribavirin Versus 3 DAAs and Ribavirin</title>
          <description>This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks post-dose (HCV RNA &lt; LLOQ at post-treatment Week 24) following treatment with 2 DAAs (ABT-450/ritonavir plus ABT-333 [Group B] or ABT-450/ritonavir plus ABT-267 [Groups C + D + J]) and ribavirin versus 3 DAAs (ABT-450/ritonavir plus ABT-333 and ABT-267) and ribavirin (Groups F + G + K + L).</description>
          <population>Intent-to-treat population; participants with missing data were counted as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.9"/>
                    <measurement group_id="O2" value="88.7"/>
                    <measurement group_id="O3" value="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The percentage of participants with SVR24 after treatment with 2 DAAs and ribavirin versus 3 DAAs and ribavirin was compared using stratum-adjusted Mantel-Haenszel (MH) method with Interleukin 28B genotype (CC or non-CC) and HCV subgenotype (1a or non-1a).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.068</p_value>
            <p_value_desc>No adjustment for multiple comparison. Pre-specified 2-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>The Mantel-Haenszel method was used because logistic regression failed due to separation or quasi-separation.</method_desc>
            <param_type>Difference</param_type>
            <param_value>-12.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.20</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
            <estimate_desc>Difference = Group B - Groups [F + G + K + L]</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The percentage of participants with SVR24 after treatment with 2 DAAs and ribavirin versus 3 DAAs and ribavirin was compared using stratum-adjusted Mantel-Haenszel (MH) method with Interleukin 28B genotype (CC or non-CC) and HCV subgenotype (1a or non-1a).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.065</p_value>
            <p_value_desc>No adjustment for multiple comparison. Pre-specified 2-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>The Mantel-Haenszel method was used because logistic regression failed due to separation or quasi-separation.</method_desc>
            <param_type>Difference</param_type>
            <param_value>-6.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.93</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
            <estimate_desc>Difference = Groups [C + D + J] - Groups [F + G + K + L]</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 3 DAAs With Versus Without Ribavirin</title>
        <description>This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks post-dose (HCV RNA &lt; LLOQ at post-treatment Week 24) following treatment with 3 DAAs with or without ribavirin (Group E versus Groups F + G + K + L).</description>
        <time_frame>Post-Treatment Week 24</time_frame>
        <population>Intent-to-treat population; participants with missing data were counted as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Group E</title>
            <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily, for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Groups F + G + K + L</title>
            <description>Participants (treatment-naïve and null-responders) received ABT-450 (100 mg or 150 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 3 DAAs With Versus Without Ribavirin</title>
          <description>This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks post-dose (HCV RNA &lt; LLOQ at post-treatment Week 24) following treatment with 3 DAAs with or without ribavirin (Group E versus Groups F + G + K + L).</description>
          <population>Intent-to-treat population; participants with missing data were counted as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6"/>
                    <measurement group_id="O2" value="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The percentage of participants with SVR24 after treatment with 3 DAAs with and without ribavirin was compared using a stratum-adjusted Mantel-Haenszel (MH) method with Interleukin 28B genotype (CC or non-CC) and HCV subgenotype (1a or non-1a).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.106</p_value>
            <p_value_desc>No adjustment for multiple comparison. Pre-specified 2-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>The Mantel-Haenszel method was used because logistic regression failed due to separation or quasi-separation.</method_desc>
            <param_type>Difference</param_type>
            <param_value>-7.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.77</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
            <estimate_desc>Difference = Group E - Groups [F + G + K + L]</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose in Treatment-naïve Versus Null-responders</title>
        <description>This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks post-dose (HCV RNA &lt; LLOQ at post-treatment Week 24) following treatment with 3 DAAs and ribavirin in participants who were treatment-naïve versus those who were null-responders to previous HCV therapy (Groups F + G + H + I versus Groups K + L + M + N).</description>
        <time_frame>Post-Treatment Week 24</time_frame>
        <population>Intent-to-treat population; participants with missing data were counted as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Groups F + G + H + I</title>
            <description>Treatment-naïve participants received ABT-450 (100 mg or 150 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 or 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Groups K + L + M + N</title>
            <description>Participants who were null-responders to previous HCV treatment received ABT-450 (100 mg or 150 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 or 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose in Treatment-naïve Versus Null-responders</title>
          <description>This outcome measure compares the percentage of participants achieving sustained virologic response 24 weeks post-dose (HCV RNA &lt; LLOQ at post-treatment Week 24) following treatment with 3 DAAs and ribavirin in participants who were treatment-naïve versus those who were null-responders to previous HCV therapy (Groups F + G + H + I versus Groups K + L + M + N).</description>
          <population>Intent-to-treat population; participants with missing data were counted as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7"/>
                    <measurement group_id="O2" value="94.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The percentage of participants with SVR24 after treatment with 3 DAAs and ribavirin in treatment-naïve versus null-responders was compared using logistic regression with treatment group, baseline log10 HCV RNA level, HCV subgenotype (1a or non-1a), geographic region (US or non-US), Interleukin 28B genotype (CC or non-CC), and ABT-450/ritonavir dose as predictors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.616</p_value>
            <p_value_desc>No adjustment for multiple comparison. Pre-specified 2-sided significance level of 0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>5.34</ci_upper_limit>
            <estimate_desc>Odds ratio: Groups [F + G + H + I] : Groups [K + L + M + N]</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 28 weeks</time_frame>
      <desc>Treatment groups differing only in ABT-450 dose (100 mg, 150 mg or 200 mg) were combined for safety analyses.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Group C + D</title>
          <description>Treatment-naïve participants received ABT-450 (100 mg or 200 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Group E</title>
          <description>Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Group F + G</title>
          <description>Treatment-naïve participants received ABT-450 (100 mg or 150 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Group H + I</title>
          <description>Treatment-naïve participants received ABT-450 (100 mg or 150 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Group J</title>
          <description>Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
        </group>
        <group group_id="E8">
          <title>Group K + L</title>
          <description>Participants who were null-responders to previous HCV treatment received ABT-450 (100 mg or 150 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.</description>
        </group>
        <group group_id="E9">
          <title>Group M + N</title>
          <description>Participants who were null-responders to previous HCV treatment received ABT-450 (100 mg or 150 mg) and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANIMAL BITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CERVICOBRACHIAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>FACIAL PARESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>AFFECTIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="66" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="74" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="40" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="36" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="34" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DISTURBANCE IN ATTENTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ABNORMAL DREAMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>DEPRESSED MOOD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>SLEEP DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>SINUS CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>PRURITUS GENERALISED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie (prior sponsor, Abbott)</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

